☆ 4.5 Editorial Material

Heart failure and dipeptidyl peptidase-4 inhibitors

EUROPEAN JOURNAL OF HEART FAILURE (2014)

期刊

EUROPEAN JOURNAL OF HEART FAILURE

卷 16, 期 6, 页码 603-607

出版社

WILEY

DOI: 10.1002/ejhf.90

关键词

-

类别

Cardiac & Cardiovascular Systems

向作者/读者索取更多资源

Protocol

Reagent

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Article Cardiac & Cardiovascular Systems

Linagliptin, A Xanthine-Based Dipeptidyl Peptidase-4 Inhibitor, Ameliorates Experimental Autoimmune Myocarditis

Yuka Shiheido-Watanabe, Yasuhiro Maejima, Takeshi Kasama, Natsuko Tamura, Shun Nakagama, Yusuke Ito, Kenzo Hirao, Mitsuaki Isobe, Tetsuo Sasano

Summary: The study demonstrated the mechanism of ameliorating experimental autoimmune myocarditis by linagliptin, showing that it reduces Th17 cells infiltration and oxidative stress in EAM hearts. It also found that the interaction between DPP-4 and cathepsin G plays a detrimental role by suppressing SerpinA3N activity.

JACC-BASIC TO TRANSLATIONAL SCIENCE (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Long-Term Dipeptidyl Peptidase 4 Inhibition Worsens Hypertension and Renal and Cardiac Abnormalities in Obese Spontaneously Hypertensive Heart Failure Rats

Edwin K. Jackson, Zaichuan Mi, Delbert G. Gillespie, Dongmei Cheng, Stevan P. Tofovic

Summary: The long-term use of DPP4 inhibitors in a rat model of spontaneous hypertension, heart failure, diabetes, obesity, and hyperlipidemia resulted in detrimental effects on blood pressure levels, renal function, and cardiac structure, indicating potential harm and the need for further investigation into the mechanisms and prevention of DPP4 inhibitor-induced pathological conditions.

JOURNAL OF THE AMERICAN HEART ASSOCIATION (2021)

添加到收藏夹

Article Medicine, Research & Experimental

Unraveling the interplay between dipeptidyl peptidase 4 and the renin-angiotensin system in heart failure

Daniel F. Arruda-Junior, Thiago A. Salles, Flavia L. Martins, Ednei L. Antonio, Paulo J. F. Tucci, Luis Henrique W. Gowdak, Caio A. M. Tavares, Adriana C. Girardi

Summary: This study found that there is an interaction between DPP4 and RAS in heart failure rats, and combined inhibition of DPP4 and RAS may not provide additional cardioprotection compared to monotherapy.

LIFE SCIENCES (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia

Dorte Vistisen, Bendix Carstensen, Patorno Elisabetta, Stefanie Lanzinger, Elise Chia-Hui Tan, Daisuke Yabe, Dae Jung Kim, Wayne H. -H. Sheu, Cheli Melzer-Cohen, Reinhard W. Holl, Julio Nunez, Kyoung Hwa Ha, Sigrun Halvorsen, Gisle Langslet, Avraham Karasik, Thomas Nystrom, Leo Niskanen, Sonia Guleria, Riho Klement, Marc Carrasco, Johannes Foersch, Christina Shay, Lisette Koeneman, Fabian Hoti, Soulmaz Fazeli Farsani, Kamlesh Khunti, Francesco Zaccardi, Anuradhaa Subramanian, Krishnarajah Nirantharakumar

Summary: This study compared the risk of cardiovascular events in patients with type 2 diabetes initiating empagliflozin compared to dipeptidyl peptidase-4 inhibitors (DPP-4i) in routine care settings in Europe and Asia. The results showed that regardless of pre-existing cardiovascular disease (CVD) or history of heart failure (HF), the use of empagliflozin resulted in lower risk of cardiovascular events.

CARDIOVASCULAR DIABETOLOGY (2023)

添加到收藏夹

Article Medicine, Research & Experimental

Dipeptidyl peptidase 4 inhibition rescues PKA-eNOS signaling and suppresses aortic hypercontractility in male rats with heart failure

Milene T. Fontes, Daniel F. Arruda-Junior, Danubia Silva dos Santos, Joao Carlos Ribeiro-Silva, Edinei L. Anto, Paulo F. J. Tucci, Luciana V. Rossoni, Adriana C. C. Girardi

Summary: This study tested the effects of DPP4 inhibitor vildagliptin on aortic hyperreactivity in male HF rats. The results showed that DPP4i mitigated the hypercontractility of HF aortas and enhanced NO bioavailability, suggesting a potential protective effect on the arteries.

LIFE SCIENCES (2023)

添加到收藏夹

Article Peripheral Vascular Disease

DPP4 (Dipeptidyl Peptidase-4) Inhibition Increases Catecholamines Without Increasing Blood Pressure During Sustained ACE (Angiotensin-Converting Enzyme) Inhibitor Treatment

Jessica R. Wilson, Erica M. Garner, Mona Mashayekhi, Scott A. Hubers, Claudia E. Ramirez Bustamante, Scott Jafarian Kerman, Hui Nian, Cyndya A. Shibao, Nancy J. Brown

Summary: DPP4 inhibition may increase catecholamine levels, but does not increase blood pressure. Increased catecholamines during concurrent use of ACE and DPP4 inhibitors may contribute to cardiovascular complications in patients predisposed to heart failure.

HYPERTENSION (2022)

添加到收藏夹

Article Endocrinology & Metabolism

Re-evaluation of dipeptidyl peptidase-4 inhibitors in patients with heart failure and diabetes mellitus

Jiaoran Li, Yanping Liu, Panpan Hao

Summary: This study aimed to evaluate the effects of DPP-4i treatment on all-cause mortality and cardiovascular outcomes in patients with heart failure. The results showed that DPP-4i treatment did not reduce the risk of all-cause death, cardiovascular death, or hospitalization for heart failure overall. However, subgroup analyses revealed that DPP-4i significantly reduced all-cause mortality in trials with more than 40% female patients and in trials with more than 20% patients with heart failure with preserved ejection fraction (HFpEF).

DIABETES RESEARCH AND CLINICAL PRACTICE (2023)

添加到收藏夹

Review Immunology

Emerging Role of Dipeptidyl Peptidase-4 in Autoimmune Disease

Jie Huang, Xinxin Liu, Yingying Wei, Xinlu Li, Shupei Gao, Lingli Dong, Xiaoquan Rao, Jixin Zhong

Summary: DPP4 is a widely expressed protease that alters the bioactivity of its substrates by cleaving off dipeptides from their N-terminus. In addition to its enzymatic functions, DPP4 is involved in various cellular processes and plays a crucial role in immune regulation and autoimmune rheumatic diseases.

FRONTIERS IN IMMUNOLOGY (2022)

添加到收藏夹

Editorial Material Cardiac & Cardiovascular Systems

Cardiovascular surrogate markers and cardiometabolic therapeutics: a viewpoint learned from clinical trials on dipeptidyl peptidase-4 inhibitors

Atsushi Tanaka, Koichi Node

Summary: Clinical trials investigating cardiometabolic therapies on cardiovascular surrogate markers can generate inconsistent and conflicting results, requiring careful investigation to understand potential cardiovascular effects. Assessing impact on surrogate markers from various perspectives and interpreting results based on clinical trial findings can aid in selecting appropriate medication tailored to individual patients.

CARDIOVASCULAR DIABETOLOGY (2021)

添加到收藏夹

Article Endocrinology & Metabolism

Effects of dipeptidyl peptidase-4 inhibitors and sulphonylureas on cognitive and physical function in nursing home residents

Andrew R. Zullo, Matthew S. Duprey, Robert J. Smith, Roee Gutman, Sarah D. Berry, Medha N. Munshi, David D. Dore

Summary: This study evaluated the effects of DPP4Is versus SUs on cognitive and physical functioning in nursing home residents. Results showed that DPP4I users had lower rates of cognitive and functional decline within 180 days, but the estimates were imprecise, calling for larger studies to provide more precise effect estimates.

DIABETES OBESITY & METABOLISM (2022)

添加到收藏夹

Article Endocrinology & Metabolism

Increasing Age Associated with Higher Dipeptidyl Peptidase-4 Inhibition Rate Is a Predictive Factor for Efficacy of Dipeptidyl Peptidase-4 Inhibitors

Sangmo Hong, Chang Hee Jung, Song Han, Cheol-Young Park

Summary: This study found that the reduction of HbA1c by DPP-4 inhibitors is associated with increasing age, and this association is linked with higher DPP-4 inhibition.

DIABETES & METABOLISM JOURNAL (2022)

添加到收藏夹

Article Geriatrics & Gerontology

Comparative safety of dipeptidyl peptidase-4 inhibitors and sulfonylureas among frail older adults

Andrew R. Zullo, Robert J. Smith, Roee Gutman, Bianca Kohler, Matthew S. Duprey, Sarah D. Berry, Medha N. Munshi, David D. Dore

Summary: This study found that among NH residents, individuals who initiated DPP4Is had a lower rate of severe hypoglycemic events compared to those who initiated SUs, with no significant differences in other severe adverse events and death rates.

JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2021)

添加到收藏夹

Article Endocrinology & Metabolism

Lower risk of hospitalization for heart failure, kidney disease and death with sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease: A retrospective cohort study in UK primary care

Iskandar Idris, Ruiqi Zhang, Jil Billy Mamza, Mike Ford, Tamsin Morris, Amitava Banerjee, Kamlesh Khunti

Summary: The study found that in patients with type 2 diabetes, sodium-glucose co-transporter-2 inhibitors (SGLT2is) were associated with significantly lower risk of all-cause mortality, cardiovascular death, and hospitalization for heart failure or chronic kidney disease compared to dipeptidyl peptidase-4 inhibitors (DPP4is).

DIABETES OBESITY & METABOLISM (2021)

添加到收藏夹

Article Endocrinology & Metabolism

DPP-4 Inhibitor and Sulfonylurea Differentially Reverse Type 2 Diabetes-Induced Blood-Brain Barrier Leakage and Normalize Capillary Pericyte Coverage

Osama F. Elabi, Dimitra Karampatsi, Ellen Vercalsteren, Grazyna Lietzau, Thomas Nystroem, Thomas Klein, Vladimer Darsalia, Cesare Patrone, Gesine Paul

Summary: Microvascular pathology in the brain is suggested to be a mechanism underlying the increased incidence and progression of neurodegenerative diseases in people with type 2 diabetes. In this study, two clinically used antidiabetic drugs, linagliptin and glimepiride, were found to restore T2D-induced brain vascular pathology and have neuroprotective effects.

DIABETES (2023)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Re-adjudication of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) with study-level meta-analysis of hospitalization for heart failure from cardiovascular outcomes trials with dipeptidyl peptidase-4 (DPP-4) inhibitors

Benjamin M. Scirica, KyungAh Im, Sabina A. Murphy, Julia F. Kuder, Dolly A. Rodriguez, Renato D. Lopes, Jennifer B. Green, Christian T. Ruff, Marc S. Sabatine

Summary: This study re-adjudicated the cardiovascular safety of Sitagliptin and performed a meta-analysis of related trials. The results showed similar incidence of heart failure between Sitagliptin and placebo, and overall no significant risk for heart failure with DPP-4 inhibitors.

CLINICAL CARDIOLOGY (2022)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Nutraceuticals in Patients With Heart Failure: A Systematic Review

Ingrid Hopper, Cia Connell, Tom Briffa, Carmine G. De Pasquale, Andrea Driscoll, Peter M. Kistler, Peter S. Macdonald, Andrew Sindone, Liza Thomas, John J. Atherton

JOURNAL OF CARDIAC FAILURE (2020)

添加到收藏夹

Review Peripheral Vascular Disease

Medical Therapies for Heart Failure With Preserved Ejection Fraction

Sverre E. Kjeldsen, Thomas G. von Lueder, Otto A. Smiseth, Kristian Wachtell, Nisha Mistry, Arne S. Westheim, Ingrid Hopper, Stevo Julius, Bertram Pitt, Christopher M. Reid, Richard B. Devereux, Faiez Zannad

HYPERTENSION (2020)

添加到收藏夹

Article Medicine, General & Internal

Impact of a model of care for heart failure in-patients to reduce variation in care: a quality improvement project

Ingrid Hopper, Kellie Easton, Illona Bader, James Campbell, Lucy Busija, Peter Markey, Peter Bergin, David Kaye

Summary: By designing a HF care model and implementing best practice guidelines, the readmission rates of patients can be reduced, and nursing outcomes improved. Results assessed using interrupted time series analysis showed significant improvements in 30- and 90-day readmissions, while emergency department representations, mortality, and length of stay remained unchanged. This care model will be adapted with the introduction of electronic medical records at the institution.

INTERNAL MEDICINE JOURNAL (2021)

添加到收藏夹

Article Endocrinology & Metabolism

Distribution of Body Hair in Young Australian Women and Associations With Serum Androgen Concentrations

Marina A. Skiba, Robin J. Bell, Rakibul M. Islam, Md Nazmul Karim, Susan R. Davis

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2020)

添加到收藏夹

Article Anesthesiology

Estimation of respiratory rate using infrared video in an inpatient population: an observational study

Peter Chan, Gabriel Wong, Toan Dinh Nguyen, Tam Nguyen, John McNeil, Ingrid Hopper

JOURNAL OF CLINICAL MONITORING AND COMPUTING (2020)

添加到收藏夹

Review Urology & Nephrology

Prevalence of Low Sexual Desire With Associated Distress Across the Adult Life Span: An Australian Cross-Sectional Study

Jia Zheng, Rakibul M. Islam, Robin J. Bell, Marina A. Skiba, Susan R. Davis

JOURNAL OF SEXUAL MEDICINE (2020)

添加到收藏夹

Article Endocrinology & Metabolism

Associations between androgens and sexual function in premenopausal women: a cross-sectional study

Jia Zheng, Rakibul M. Islam, Marina A. Skiba, Robin J. Bell, Susan R. Davis

LANCET DIABETES & ENDOCRINOLOGY (2020)

添加到收藏夹

Article Public, Environmental & Occupational Health

Prevalence of and Risk Factors for Depressive Symptoms and Antidepressant Use in Young Australian Women: A Cross-Sectional Study

Rakibul M. Islam, Lucy Marsh, Robin J. Bell, Marina A. Skiba, Susan R. Davis

Summary: The prevalence of moderate to severe depressive symptoms among young Australian women is concerning, with housing insecurity being a significant risk factor. The use of psychotropic medication is common, with factors such as age, parity, and ethnicity playing a role in antidepressant use.

JOURNAL OF WOMENS HEALTH (2021)

添加到收藏夹

Editorial Material Medicine, General & Internal

Complementary medicine use by community-dwelling older Australians

Aimee Lefevre, Ingrid Hopper, John J. McNeil, Alice Owen

MEDICAL JOURNAL OF AUSTRALIA (2021)

添加到收藏夹

Article Endocrinology & Metabolism

Differing performance of two assays for the measurement of anti-Mullerian hormone in premenopausal women: A cross-sectional study

Robin J. Bell, Marina A. Skiba, Ken Sikaris, Angela Liu, Rakibul M. Islam, Susan R. Davis

Summary: The study compared two commercially available AMH assays and found that despite a high correlation, the assays performed differently at high and low concentrations. Therefore, the results of these assays are not interchangeable, emphasizing the importance of establishing specific reference values for individual assays to guide clinical decision-making and the challenge of establishing future universal cutoffs for the application of AMH levels in clinical practice.

CLINICAL ENDOCRINOLOGY (2021)

添加到收藏夹

Article Obstetrics & Gynecology

Use of community-based reference ranges to estimate the prevalence of polycystic ovary syndrome by the recognised diagnostic criteria, a cross-sectional study

Marina A. Skiba, Robin J. Bell, Dilinie Herbert, Alejandra Martinez Garcia, Rakibul M. Islam, Susan R. Davis

Summary: Despite applying stringent criteria for the diagnosis of PCOS in a non-healthcare seeking community-based sample, there remains a risk of diagnostic uncertainty in identifying women with PCOS.

HUMAN REPRODUCTION (2021)

添加到收藏夹

Article Surgery

Identification of Predictive Factors for Patient-Reported Outcomes in the Prospective Australian Breast Device Registry

Jessy Hansen, Susannah Ahern, Pragya Gartoulla, Ying Khu, Elisabeth Elder, Colin Moore, Gillian Farrell, Ingrid Hopper, Arul Earnest

Summary: This study developed risk-adjustment models for benchmarking patient-reported outcome measures (PROMs) in breast device procedures. The models help accurately track device outcomes and identify outliers in an equitable manner.

AESTHETIC SURGERY JOURNAL (2022)

添加到收藏夹

Article Medicine, Legal

Final opinion on the safety of breast implants in relation to anaplastic large cell lymphoma: Report of the scientific committee on health, emerging and environmental risks (SCHEER)

Wim H. De Jong, Demosthenes Panagiotakos, Ana Proykova, Theodoros Samaras, Mark W. Clemens, Daphne De Jong, Ingrid Hopper, Hinne A. Rakhorst, Fabio Santanelli di Pompeo, Suzanne D. Turner

Summary: The SCHEER was requested to provide a scientific opinion on the safety of breast implants in relation to ALCL by the EC. Different surface textures of breast implants may present different risks, but the causality between textured breast implants and BIA-ALCL is considered moderate. New cases reported by national clinical registries are crucial for estimating the risk of BIA-ALCL.

REGULATORY TOXICOLOGY AND PHARMACOLOGY (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Impact of Late Referral on Cardiac Transplant Outcomes

Elizabeth Suo, Ingrid Hopper, Su Ling Tee, Hitesh C. Patel, David M. Kaye

Summary: This study evaluated the impact of late referral for heart transplantation on outcomes. Late referral was defined as the presence of four or more out of 10 criteria for more than 6 months in heart transplantation patients. Patients who were referred late were more unwell at the time of referral and incurred greater in-hospital costs.

HEART LUNG AND CIRCULATION (2022)

添加到收藏夹

Article Health Care Sciences & Services

Exploring staff perspectives on caring for isolated hospitalised patients during the COVID-19 pandemic: a qualitative study

Robin Digby, Ingrid Hopper, Leanne Hughes, Doug McCaskie, Michelle Tuck, Kethly Fallon, Peter Hunter, Tracey Bucknall

Summary: This study aimed to understand staff perceptions and interpretations of their experiences of the care and treatment of isolated patients and the impact of isolation on patients, families, and staff. It found that isolating patients and restricting visitors resulted in good pandemic management, but came at considerable cost to staff and consumers. Appropriate interventions are needed to improve care.

BMC HEALTH SERVICES RESEARCH (2023)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.